\
&
Contact us
\
&
Contact us
Starts in 1 month from now
LocationUniversity College Dublin
Advancing Deep Tech Value, Acceleration and New Competitiveness in Europe
ADVANCE is an official Irish Presidency of the Council of the European Union event hosted by University College Dublin (UCD) and supported by the EIC and Enterprise Ireland.
Advancing Deep Tech Value, Acceleration and New Competitiveness in Europe by bringing together founders, policymakers, investors, industry leaders, universities, innovation agencies and accelerators to assess Europe’s progress in supporting start-ups, scale-ups and deep-tech ventures.
The programme will explore persistent barriers to scaling and identify practical actions to strengthen Europe’s competitiveness and innovation ecosystem.
Please note that, due to the enhanced security arrangements in place for the conference, all participants will be required to complete an accreditation process. To secure your place, we kindly ask you to register your interest via the conference website: https://www.eicadvance2026.eu/.
Following registration, you will receive an individual link with instructions to complete the required accreditation process.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
